HCM — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00
- £2.30bn
- £1.76bn
- $838.00m
- 26
- 10
- 63
- 21
RCS - Hutchmed China Ltd - Japan Bridging Study For Surufatinib Initiated
AnnouncementRCS - Hutchmed China Ltd - Breakthrough Therapy Designation for Amdizalisib
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and AZ Initiate Phase III Trial in China
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Present Clinical Data at ESMO
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Shares Included in Stock Connect Programs
AnnouncementREG - Hutchmed China Ltd - Grant of Share Options, and Awards under LTIP
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - Phase Ib/II Trial of Fruquintinib & Tislelizumab
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Selected for Certain Hang Seng Indexes
AnnouncementREG - Hutchmed China Ltd - ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
AnnouncementREG - Hutchmed China Ltd - HUTCHMED & Epizyme Announce TAZVERIK Collaboration
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Interim Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Phase II Trial of ORPATHYS Initiated
AnnouncementREG - Hutchmed China Ltd - Stabilizing Actions & End of Stabilization Period
AnnouncementREG - Hutchmed China Ltd - Holding(s) in Company
AnnouncementRCS - Hutchmed China Ltd - Surufatinib MAA Submitted and Validated by the EMA
AnnouncementREG - Hutchmed China Ltd - Holding(s) in Company
AnnouncementRCS - Hutchmed China Ltd - First Commercial Sale of ORPATHYS® in China
Announcement